238 related articles for article (PubMed ID: 15504711)
1. Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.
Theuer CP; Leigh BR; Multani PS; Allen RS; Liang BC
Biotechnol Annu Rev; 2004; 10():265-95. PubMed ID: 15504711
[TBL] [Abstract][Full Text] [Related]
2. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
3. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
5. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Grillo-López AJ
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
[TBL] [Abstract][Full Text] [Related]
6. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
White CA
Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
[TBL] [Abstract][Full Text] [Related]
7. Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan.
Hendrix C
Clin J Oncol Nurs; 2004 Feb; 8(1):31-4. PubMed ID: 14983760
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
[TBL] [Abstract][Full Text] [Related]
12. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Dillman RO
Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
[TBL] [Abstract][Full Text] [Related]
14. Future directions in radioimmunotherapy for B-cell lymphoma.
Horning SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
[TBL] [Abstract][Full Text] [Related]
15. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma.
Grillo-López AJ
Expert Rev Anticancer Ther; 2002 Oct; 2(5):485-93. PubMed ID: 12382517
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
[TBL] [Abstract][Full Text] [Related]
17. Rituximab: ongoing and future clinical development.
Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
[TBL] [Abstract][Full Text] [Related]
18. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
20. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Gordon LI
Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
